BidaskClub downgraded shares of Dova Pharmaceuticals (NASDAQ:DOVA) from a buy rating to a hold rating in a research note published on Saturday morning.
A number of other analysts also recently issued reports on the company. Zacks Investment Research downgraded Dova Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, November 14th. Jefferies Group lifted their price objective on Dova Pharmaceuticals to $33.00 and gave the stock a buy rating in a research note on Tuesday, November 28th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of Buy and a consensus price target of $32.75.
Shares of Dova Pharmaceuticals (NASDAQ:DOVA) opened at $31.18 on Friday. Dova Pharmaceuticals has a 12 month low of $16.98 and a 12 month high of $37.00.
Several institutional investors have recently made changes to their positions in the company. Pier Capital LLC boosted its holdings in shares of Dova Pharmaceuticals by 37.2% in the 4th quarter. Pier Capital LLC now owns 160,123 shares of the company’s stock worth $4,612,000 after purchasing an additional 43,408 shares during the period. Nexthera Capital LP boosted its holdings in shares of Dova Pharmaceuticals by 3.4% in the 4th quarter. Nexthera Capital LP now owns 453,032 shares of the company’s stock worth $13,047,000 after purchasing an additional 14,913 shares during the period. Perceptive Advisors LLC boosted its holdings in shares of Dova Pharmaceuticals by 3.1% in the 4th quarter. Perceptive Advisors LLC now owns 1,809,015 shares of the company’s stock worth $52,099,000 after purchasing an additional 55,000 shares during the period. Goldman Sachs Group Inc. purchased a new position in shares of Dova Pharmaceuticals in the 4th quarter worth approximately $461,000. Finally, Deutsche Bank AG boosted its holdings in shares of Dova Pharmaceuticals by 139.2% in the 4th quarter. Deutsche Bank AG now owns 11,748 shares of the company’s stock worth $337,000 after purchasing an additional 6,836 shares during the period. Hedge funds and other institutional investors own 26.93% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Dova Pharmaceuticals (DOVA) Rating Lowered to Hold at BidaskClub” was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3227052/dova-pharmaceuticals-dova-rating-lowered-to-hold-at-bidaskclub.html.
About Dova Pharmaceuticals
Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.